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Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of 
hypersalivation induced by clozapine (GOTHIC1): a feasibility study 
 
ABSTRACT 
 
Background: Clozapine-induced hypersalivation (CIH) is a common side effect of clozapine 
treatment and is disliked by clozapine patients, potentially threatening adherence to 
clozapine treatment. We proposed a trial of alternative medications, hyoscine and 
glycopyrrolate, for the treatment of CIH and the primary objective of the feasibility study 
was to assess the recruitment and retention of community clozapine patients as well as 
assess the metrics of the primary hypersalivation measure.  
Methods: This 11-month trial took place in two NHS trusts in northwest UK. Participants 
were community-dwelling clozapine patients aged 18-65 years who were suffering from CIH, 
and were recruited from community mental health clinics. They were randomised using a 
telephone randomisation service to receive either hyoscine (1 week at 0.6mg daily, 3 weeks 
at 0.9mg daily), glycopyrrolate (1 week at 2mg daily, 3 weeks at 3mg daily) or placebo. 
Participants and investigators were blinded to which study arm the participants had been 
randomised to. We collected data on salivation levels and side effects on a weekly basis and 
also assessed cognition at the beginning and end of the trial. We also interviewed a sample 
of participants after the trial to gather information on their experience of having taken part. 
Results: 138 potential participants agreed to being contacted by researchers about 
participation in the trial and of these, 29 participants were randomised. Of these, four 
participants exited the trial before taking any trial medication, and two participants left the 
study owing to concerns of side effects. Data from four participants was missing, and 
complete data was available for 19 participants who competed the trial. The mean 
recruitment rate overall was 1.3 participants per site per month, and the overall retention  
rate was 76%. Interview data suggested that participants’ experiences of trial participation 
was overwhelmingly positive. 
Conclusions: The feasibility study demonstrated that a trial of alternative medications in the 
treatment of CIH is feasible; patients were willing to be randomised to the trial and 
retention rate was high.  
Trial registration: ClinicalTrials.gov NCT02613494, registered 24 November 2015. 
https://clinicaltrials.gov/ct2/show/NCT02613494 
 
KEYWORDS 
 
Clozapine-induced hypersalivation, drooling, glycopyrrolate, hyoscine, feasibility study, 
refractory schizophrenia, side effects, cognition. 
 
  
3 
 
BACKGROUND 
 
Clozapine is the only medication licensed for the treatment of resistant schizophrenia and in 
almost all cases is a lifelong prescription [1]. Clozapine-induced hypersalivation (CIH) is a 
common side effect of clozapine treatment, occurring at any stage of treatment in greater 
than 90% of patients [2]. CIH carries with it a profound social stigma, lowering self-esteem, 
increasing social isolation and exacerbating psychological problems [3]. It can cause 
inflammation of the salivary glands, surrounding skin infections [4] and affect sleep quality 
[3]. A survey of patients prescribed clozapine found that hypersalivation was the most 
unacceptable side-effect of clozapine treatment and crucially, the burden of adverse side-
effects may eventually lead to patients discontinuing clozapine treatment [5]. Therefore, 
effective treatment of CIH is vital to patient experience and wellbeing. 
In the UK the most commonly used medication for CIH is hyoscine hydrobromide 
(‘hyoscine’), an anti-muscarinic licensed as a motion sickness prophylactic and as a pre-
operative drug to dry secretions. This is partly because CIH is listed as an unlicensed use for 
hyoscine in the British National Formulary [6]. However there is no convincing evidence for 
any drug as an effective treatment for CIH [7-9] although one recent small trial has shown 
encouraging results with hyoscine [10]. Additionally, a wide range of side-effects have also 
been linked to hyoscine [11-12], most commonly drowsiness, dizziness and constipation 
(which can be a lethal side effect of clozapine treatment). Because it crosses the blood-brain 
barrier, hyoscine may also cause cognitive deficits, including impairments of visual and 
verbal memory [13]. This is significant because cognitive deficits in schizophrenia are 
common and associated with poor long-term outcomes [14].  
Glycopyrronium bromide (‘glycopyrrolate’) is an anti-muscarinic with poor blood-
brain-barrier penetration [15]. It is widely used in the UK as a pre-anaesthetic agent because 
of its long-lasting ability to decrease salivary production and gastric acid, and it is commonly 
prescribed by paediatricians in the treatment of drooling in children with neuro-
developmental disorders (e.g. cerebral palsy). A small (n=13) double-blind, randomised 
crossover study of glycopyrrolate and biperiden (a centrally acting anticholinergic similar to 
hyoscine) in CIH reported reduced hypersalivation scores in patients receiving 
glycopyrrolate [16]. Importantly, cognitive functioning assessment scores showed a 
significant reduction for participants receiving biperiden but not for glycopyrrolate. The 
authors concluded that glycopyrrolate could be a valid treatment for CIH although larger 
trials were required to confirm the finding. A Cochrane review [7] of the evidence base for 
the efficacy of pharmacological treatments for CIH concluded ‘there are currently 
insufficient data to confidently inform clinical practice, limitations of these studies are 
plentiful and the risk of bias high’ and ‘it seems reasonable to trial safe interventions for 
which there is a rationale’.  
A large RCT is therefore required to evaluate the efficacy of hyoscine and glycopyrrolate, 
in comparison to placebo, in the treatment of CIH. However such a trial presents a number 
of challenges including whether potential participants with CIH would agree to be 
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randomised to a placebo arm, whether the proposed trial design and schedule of 
assessments would be acceptable to potential participants and establishing the metrics of 
the primary outcome measure to measure drooling.  Therefore we conducted a feasibility 
study as a step towards a future large RCT. The feasibility study aims were to:  
 
1. Ascertain whether the proposed study design is acceptable to participants, including 
randomisation and use of telephone interviews to obtain data. 
2. Ascertain whether the study interventions are acceptable to participants and indicate 
attrition rates and tolerability. 
3. Assess the standard deviation of the proposed primary outcome measure, the Drooling 
Rating Scale, to inform a sample size calculation for a future efficacy RCT. 
 
METHODS 
 
The reporting of the study follows the CONSORT statement recommendations [17]. 
 
Design 
This 11-month feasibility study was a multi-centre, double-blind, randomised placebo-
controlled trial of two investigational medicinal products (IMPs), hyoscine and 
glycopyrrolate, in the treatment of male and female patients with clozapine-induced 
hypersalivation.  
 Patients were closely involved throughout the development and design of the study. 
The initial research question was inspired by views of the side effects of clozapine treatment 
gathered from our patients [5], and the design of the study benefited from the views of 
service users who advised on the acceptability of the proposed recruitment strategy and 
trial procedures. A service user researcher also joined the Trial Management Group to assist 
in overseeing the study.  
Patients were randomized in a 1:1:1 ratio to one of three treatment arms, hyoscine, 
glycopyrrolate or placebo. Participants who were already taking medication for 
hypersalivation when joining the study had that medication stopped for one week (the 
‘washout’ period) prior to taking the IMP. Baseline measures of cognition, hypersalivation 
and side effects were measured prior to taking the IMP. In week 1 of the intervention, 
participants were administered a lower dose of IMP (0.3mg hyoscine twice daily, or 1mg of 
glycopyrrolate twice daily). In weeks 2-4 of the intervention, participants were administered 
a full dose of IMP (0.3mg hyoscine three times daily, or 1mg of glycopyrrolate three times 
daily). Hypersalivation and side effects were measured at the end of weeks 1-4, and 
cognition was measured again at the end of week 4. A four week intervention is consistent 
with other clozapine-induced hypersalivation trials [10,17] to allow for estimation of 
attrition rate.  
 A CONSORT diagram showing key stages of the study design is presented in Fig 1.  
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- Figure 1 here - 
Recruitment 
 The target number of patients with complete data at baseline and follow up in each of the 
three study arms was 14, and 42 in total, from three study sites. The sample size was 
determined by a number of factors. Forty-two would allow an estimate of the metrics for 
the primary outcome measure (Drooling Rating Scale) [18] and also allow an assessment of 
the recruitment and attrition rate, easily accommodating the 12-per-group rule-of-thumb 
recommended by Julious [19]. Both of these factors are feasibility aims. The predicted 
attrition rate was estimated at 20% using a conservative approximation based on previous 
studies using similar populations [10,16]. 20% attrition allows clear differentiation from the 
progression criterion (see below; 40% attrition), with >80% power to detect a difference of 
this size with alpha 0.25 (1 tailed). This is consistent with the relaxed power and alpha 
criteria suitable for an early phase trial of this type [19,20], specifically the alpha 0.25 
criterion advocated by Schoenfeld [21]. 
Recruitment commenced in January 2017. Participants were included in the study if 
they were English-speaking, community-dwelling, between the ages of 18 and 65 years, 
prescribed clozapine for a minimum of three months, and experiencing hypersalivation. 
They were excluded if they had any medical conditions that affected hypersalivation (e.g. 
idiopathic Parkinson’s Disease), neurological conditions that affected cognitive functioning, 
history of allergic reactions, contraindications or cautions to hyoscine or glycopyrrolate, 
prescribed other medications with a significant anticholinergic profile, or experiencing 
suicidal ideation. 
Patients attending their regular community clozapine clinic appointment were 
approached by the clinic team about possible participation in the study. Once consent to 
contact was obtained, the research team contacted the patient to provide written 
information about the study, followed up with a telephone call at least 2 days later and 
formal consent was taken by a researcher who visited the patient’s home. Occasionally, a 
researcher was present in the clozapine clinic when the patient was first approached by 
clinic staff and if the patient expressed interest in the trial, they were introduced to the 
researcher who was then able to explain the trial in more detail and provide written 
information. Under these circumstances, the researcher still followed up by telephone at 
least two days later before arranging formal consent. Following formal consent, the 
researcher accessed the patient’s medication details from their GP to confirm eligibility. The 
Chief Investigator formally confirmed eligibility before patients were randomised.  
Midway through the study, clinic staff suggested that patients might be more 
receptive to participation if they were already aware of the existence of the study prior to 
being approached about it by staff. In response to this, posters advertising a research study 
on medication to treat clozapine-induced hypersalivation were placed in clinic waiting areas 
to raise awareness. Clinic staff subsequently reported anecdotally that potential participants 
appeared more amenable to hearing more about the study when they were approached.  
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Randomization procedure 
Randomisation services were provided by Manchester Academic Health Sciences Centre – 
Clinical Trials Unit (MAHSC-CTU). The trial was blinded with three arms to be allocated in a 
1:1:1 ratio. A computer generated list was drawn up by a statistician at MAHSC-CTU for 42 
allocations and supplied to the trial pharmaceutical company to facilitate preparation and 
labelling of the bottles.  
Once eligibility was confirmed by the Chief Investigator, the patient was randomized 
to one of the treatment arms. Third-party randomization took place by telephone call to 
MAHSC-CTU. The researcher provided the participant’s initials, gender and date of birth, 
and the randomization service returned a participant ID number and bottle number. The 
bottle number corresponded to numbered sets of IMP held by the trial pharmacy. The 
participant’s ID number was recorded in the case report form and on all study 
documentation related to that participant.  
 
Medication and blinding 
IMPs and placebo were overencapsulated by the trial pharmaceutical manufacturer 
(Catalent UK) to look identical. Medication was bottled in study kits comprising one Week 1 
bottle (containing 14 capsules) and three other bottles (each containing 21 capsules) for 
Weeks 2-4. The manufacturer labelled all medication bottles with bottle numbers under 
instruction from MAHSC-CTU who kept the list of bottle numbers and corresponding 
medication contents. MAHSC-CTU provided the trial pharmacy with a sealed list of bottle 
numbers and contents in the event that emergency unblinding was required.  
 Neither the participants nor the research team were aware of the trial arm to which 
any participant had been assigned. This was revealed to the study team by MAHSC-CTU only 
at the end of the trial. Following the end of the trial, the study team wrote to all participants 
to relay this information and thank them for their help in participating.  
 
Study visits and data collection 
Formal consent and data collection was completed during visits to the participants’ homes 
or occasionally at a suitable alternative location (e.g. community clinic) if participants 
preferred not to have visitors at home. There were four visits (consent, baseline, 
maintenance, final) in total, with two additional visits (medication collection, exit interview) 
if optionally required.  
 In the consent visit, participants who had verbally agreed to take part in the study 
were visited by a researcher to answer any questions and clarify any study participation 
issues. At this visit, participants signed the consent form. Subsequent to this, further 
eligibility checks were completed using the participant’s medical history and current 
medications list, and when the Chief Investigator confirmed eligibility, the participant was 
randomised to the study. During the baseline visit at the beginning of Week 1, participants 
completed measures of cognition, salivation and side effects and were given a one-week 
supply of IMP. During the maintenance visit (at the end of Week 1), participants were visited 
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to complete the salivation and side effects measures, and were also given a three-week 
supply of IMP. At the end of Week 2 and Week 3, participants were telephoned to complete 
the salivation and side effects measures. In the final visit at the end of Week 4, participants 
completed measures of cognition, salivation and side effects.  
Two other optional visits were possible. If prior to joining the study, the participant 
had been taking mediation for salivation, this was removed from them during a medication 
visit that took place one week prior to the baseline visit. Also, at the end of the study, 
participants were given the option of taking part in an exit interview that would be 
conducted by an expert-by-experience (i.e. a service user or carer with personal lived 
experience of mental health services) to gather participant views of their experience of 
taking part in the study. If participants agreed to this, they were contacted by an expert-by-
experience researcher within two weeks to arrange an exit interview. All participants who 
dropped out of the study after having started on the intervention phase were approached 
for an exit interview. Research assistants also approach approximately every third 
participant who completed the study. 
The stages of the trial design in each phase are shown in Fig. 1. 
 
Outcomes 
The primary outcome measure was the overall recruitment level and retention rate for the 
study. The secondary outcome measure was the level of salivation reported using the 
Drooling Rating Scale, specifically the mean and standard deviation for this measure in the 
target population. 
 The criteria for progression to a full randomised controlled trial were set at: 1. a 
recruitment rate at a minimum of one participant per site per month and, 2. an overall 
attrition rate of less than 40%.  
 
Feasibility measures 
The recruitment rate was calculated by dividing the total number of consented participants 
by the number of active recruiting sites, and the attrition rate was the total proportion of 
consented participants who left the study before completing the intervention phase. Both 
indicators were standing items for discussion at all Trial Management Group meetings. 
 
Study measures 
During the study, salivation was measured using the Drooling Rating Scale and the Nocturnal 
Hypersalivation Rating Scale, cognition was measured using the Brief Assessment of 
Cognition in Schizophrenia, and side effects were measured by the Liverpool University 
Neuroleptic Side-Effect Rating Scale.  
 The Drooling Rating Scale (DRS). The DRS [18] is a two-item scale comprising drooling 
severity and frequency assessments that combine to form a score ranging from 2 - 9. Whilst 
it has not been validated and its metrics (standard deviation, mean, sensitivity to change) 
are unknown in a UK clozapine-induced hypersalivation population, it has good face validity 
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and has been used in published research on paediatric hypersalivation. DRS was used 
weekly to assess daytime hypersalivation and establishing its metrics in a UK CIH population 
was a feasibility aim. 
 The Nocturnal Hypersalivation Rating Scale (NHRS). The NHRS [22] is a validated 
single-item 5-point self-report scale for measuring the degree of nocturnal salivation that a 
respondent experiences. The NHRS is the only scale specifically mentioned in the Cochrane 
review for treatments for CIH that is recommended for inclusion in future studies of the 
efficacy of CIH interventions.  
 Brief Assessment of Cognition in Schizophrenia (BACS). The BACS [23,24] comprises a 
short battery of tests devised for easy administration and scoring which assess the extent of 
cognitive impairment in schizophrenia. The battery includes brief assessments of executive 
function, verbal fluency, attention, verbal memory, working memory and motor speed, and 
requires approximately 30 minutes to complete. The BACS has high test–retest reliability in 
people with schizophrenia and healthy controls, and has been shown to be as sensitive as a 
standard 2.5-hour test battery.  
 Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS). LUNSERS [25] is 
a 51-item checklist of side-effects which asks for ratings on a 5-point scale of the degree to 
which respondents have experienced that side effect in the last month. It can be completed 
in less than 10 minutes and shows good reliability and validity, correlating well with other 
clinician-administered side effect scales. A modified LUNSERS was used to assess side-
effects in the previous week (rather than month). 
 Exit interviews. A subset of participants also completed an exit interview conducted 
by an expert-by-experience researcher. Semi-structured interviews explored the 
participant’s experience of taking part in the study, covering the acceptability of the study 
methods and soliciting advice on how their study participation experience could have been 
improved. Exit interviews were requested with all participants who did not complete the 
study, and a selection of completing participants. 
 
Data security and monitoring 
Data entry was completed by the research assistants and validated by the Study Manager 
who completed validation checks on a minimum of 10% of the complete participant data. All 
source data and trial documentation were made available to MAHSC-CTU for study 
monitoring. Participants consented to this within the consent process.  
 Participant contact details were disclosed to the research assistants for the purposes 
of arranging consent and data collection visits. All participant data collected by the research 
assistant were identified using the participant’s study code and initials. Identifiable 
participant information was kept in a locked filing cabinet and separate from the 
participant’s study data.  
Study monitoring was conducted by MAHSC-CTU. The Quality Assurance monitor 
checked case report forms, trial master file and other trial documentation for completeness 
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and the compliance of the trial team with the protocol and good clinical practice (GCP) 
standards.  
 
Trial Management Group  
The Trial Management Group was formed comprising the chief investigator, co-
investigators, study manager, research assistants, MAHSC-CTU representatives, service user 
representative, and pharmacy representative. The group met every two months.  
 
Ethical approval and consent 
The study was conducted in accordance with the ethical principles prescribed in the 
Declaration of Helsinki. The patients were given an information sheet for consideration and 
given a minimum of two days to decide on participation. Written informed consent was 
obtained at a consent interview and patients were given an opportunity to ask questions 
before completing the consent form. Formal consent was obtained before any study 
procedures took place.  
 Ethical approval for the study was granted by the Health Research Authority, North 
West - Greater Manchester East Research Ethics Committee (reference 15/NW/0823).  
 
Study sites and data collection 
Mersey Care NHS Foundation Trust opened as a study site in January 2017. Mersey Care 
operates three community clozapine clinics, with approximately 400 registered patients in 
total, and patients at all three clinics were approached about participation by clinic staff. 
Lancashire Care NHS Foundation Trust was opened as a study site in February 2017 and 
eight of the community clozapine clinics, with approximately 600 registered patients, were 
recruited from. The third study site was not opened due to internal service re-organisation 
at that site and consequently in August 2017, with the agreement of research funding body, 
the recruitment target was adjusted from 42 participants across three sites to 28 
participants across two sites.  
One researcher omitted to enter participant data centrally during data collection and 
missing data for four participants was reported to the Health Research Authority (HRA) in 
November 2018 as a protocol breach.  
 
ANALYTIC STRATEGY 
 
Quantitative data 
No hypothesis testing was conducted as the feasibility aims were to assess the recruitment 
and retention rates in the target population and establish the metrics of the putative 
primary outcome measure; the mean and standard deviation for this measure are reported. 
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Qualitative data 
Exit interviews were conducted with participants after they completed (or dropped out of) 
the trial in order to gather information on their experience of trial participation and trial 
procedures. This was to acquire an understanding of how a future trial could be designed 
and common themes are reported.  
- Figure 2 here -  
RESULTS 
Table 1. Age and gender distribution in each arm at time of randomization 
Arm Age in years Frequency (gender) 
Hyoscine 25-34 0 
 35-44 5 (2 female, 3 male) 
 45-54 2 (2 male) 
 55-64 2 (2 male) 
Glycopyrrolate 25-34 1 (1 male) 
 35-44 4 (4 male) 
 45-54 2 (1 female, 1 male) 
 55-64 2 (2 male) 
Placebo 25-34 3 (1 female, 2 male) 
 35-44 4 (1 female 3 male) 
 45-54 2 (2 male) 
 55-64 2 (2 male) 
 
Recruitment and retention 
The number of patients assessed for eligibility, randomized and excluded, and the number 
of complete datasets assessed in each trial arm, are presented in the CONSORT diagram in 
Fig. 2.  
A total of 138 patients consented to being contacted by a researcher and 29 
participants were randomised to the study; this represents 21% of participants that agreed 
to be contacted and Table 1 shows the demographic details of the sample. Nine participants 
were randomised to the hyoscine arm, nine to the glycopyrrolate arm and eleven to the 
placebo arm. However, four participants (all from the hyoscine arm) exited the study before 
starting the intervention phase of the trial: two participants changed their minds and gave 
no further reason for leaving the study; one participant left due to a change in personal 
circumstances; one participant did not respond to contact after having been randomised 
and was withdrawn after six weeks of no contact. 82% of randomised participants therefore 
received study medications.  
In terms of acceptability of the study design, using telephone interviews to collect 
data, we established this was both acceptable to participants and viable in practice.   
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Tolerability of the study drugs 
Of the 24 participants who received study medication only two participants exited during 
the study intervention phase. Both these participants were in the placebo arm; one 
participant perceived their hypersalivation to be worsening and one participant left the trial 
because their blood tests, conducted as part of normal clozapine treatment monitoring, 
showed abnormal results and although this was unlikely to be linked to the trial medication, 
decided to leave the trial. Nevertheless, data from these participants were still included in 
assessing the trial objectives as they were able to provide measures of salivation using the 
DRS during the baseline phase and were able to contribute data to the assessment of 
recruitment and attrition.  
There were no dropouts from either the hyoscine or glycopyrrolate arms 
demonstrating these medications were well tolerated and no serious adverse events were 
reported during the trial. There was one report of a medication error; a participant was 
prescribed medication for hypersalivation prior to being recruited to the trial and an error 
resulted in their previous hypersalivation medication being prescribed concurrently with 
trial medication. The error was noticed after three days and trial medication was stopped 
immediately. The participant re-joined the trial later after the previous medication was 
confirmed to have been removed. This event led the research team to improve the 
procedure on confirming that relevant prescribed medication had been discontinued.  
In summary our recruitment and retention aims were met as 29 participants were 
recruited that met the revised recruitment target demonstrating the trial design was 
acceptable.  Study participants found the medications to be tolerable and the attrition rate 
was 24% which was significantly less than the 40% attrition rate identified a priori as the 
progression criterion.  
 
Parameters of primary outcome measure 
A secondary aim of the trial was to establish the baseline metrics of the DRS. Twenty-one 
participants (19 participants who completed the trial and 2 participants who dropped out 
after receiving trial medication) provided hypersalivation data using the DRS when baseline 
measurements were recorded. The mean DRS score at baseline was 5.14 and the standard 
deviation was 1.68.  
 
Table 2. Main themes with illustrative quotations from the exit interviews with 7 
participants.  
Recruitment was well informed 
“I did have some questions about effectiveness and side effects but I was ok with the 
responses from the [clinic nurses]. It might have been better if you [the researcher] were 
in the room when I was first asked so you could answer my questions – I think it’s better 
to have someone there the first time people are asked about it.” [P13] 
“I felt like it was quite thorough.” [P25] 
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 “I was nervous at first and had some questions about side effects and the nurses didn’t 
really know but when I spoke to [the researcher], she was able to answer these and she 
was reassuring that I didn’t have to take part and if I did I could stop whenever. But yeah 
I had to wait to speak [the researcher] and it would be better to have those questions 
answered there and then.” [P14] 
“Yeah I knew everything I needed to know.” [P06] 
Trial procedures were acceptable 
“The cognitive test thing was fairly interesting to do – it was something different.” [P13] 
“The tests were fun in a way. 45 minutes is a long time but actually it was fun. I didn’t 
realise the time had gone by.” [P14] 
“I think it went really well. The meetings and phone calls weren’t too much.” [P23] 
“I think it went alright. I can’t see any improvement on it. I wouldn’t change anything.” 
[P23] 
 
 
Exit interviews 
A service user researcher, accompanied by a researcher, conducted seven exit interviews 
with participants. Six interviews were conducted with participants who completed the trial 
and one interview with a participant who withdrew from the study owing to worsening side 
effects (excessive salivation). The primary aim of the exit interviews was to assess the 
participants’ experiences of trial participation and to obtain suggestions about changes that 
may have improved their experience.  
Two main themes emerged from our analysis of the exit interviews namely that 
consent was well informed and trial procedures were acceptable. The themes together with 
illustrating quotations are presented in Table 2. The recruitment method, washout period, 
trial procedures and data collection were all reported as acceptable and no respondents 
raised any difficulties with any of the trial processes. Without exception, all interviewees 
expressed very positive views of trial participation. Data from exit interviews also suggested 
that participants were reassured by the presence of a researcher during recruitment who 
was able to answer questions about the trial (see quotations from P13 and P14 in Table 2) 
and that this was an important aspect of successful recruitment. This aspect of the 
recruitment strategy is something that we aim to strengthen in the future efficacy trial by 
having a researcher present at the initial approach to potential participants.  
 
DISCUSSION 
The trial presented several challenges in an under-researched population and has provided 
important information for the design and conduct of a future RCT. A major aim of the 
feasibility study was to assess recruitment strategies and recruitment rates and explore how 
these could be improved for future studies. We found our trial design to be acceptable and 
138 patients agreed to receive further information about the trial of which 29 were 
eventually randomised. Across two sites and 11-months, this equated to 1.3 participants per 
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site per month, which comfortably exceeded our a priori progression criterion for 
recruitment rate of 1 participant per site per month. The presence of a researcher in the 
clozapine clinics during recruitment, who could explain the trial in detail and answer 
questions, proved to be an important factor in improving recruitment. Valuable lessons 
were also learned liaising and maintaining relationships with clozapine clinic staff making 
the initial approaches to patients and promoting the trial to patients using posters before 
they were approached.  
 Our results also confirmed that participants found the design to be acceptable and 
medications to be tolerable; the attrition rate was 24% which comparable to that found in 
other trials involving patients with clozapine-induced hypersalivation [10] and was lower 
than the 40% attrition rate identified a priori as a criterion for progression. Participants 
were in weekly contact with a researcher throughout the intervention phase and it is likely 
that this level of involvement and engagement with the research team contributed to low 
levels of attrition.  
Of the 138 patients who agreed to be contacted by a researcher about participation 
in the study, 29 ultimately consented to participation. Of the remaining 109 patients, 8 were 
found to be ineligible, 26 declined to take part in the study after hearing more details about 
it, and 21 could not take part for other miscellaneous circumstances (e.g. could not begin 
study participation before the end of study date, going on holiday). Fifty-four patients could 
not be contacted to follow up on their initial expression of interest and, in these cases, the 
patient left an address and telephone number as their contact details but later failed to 
answer numerous attempts at telephone contact by the researcher. After a week, the 
patient was sent a letter thanking them for their interest in hearing more about the study, 
and asking them to telephone the research office if they would like to hear more. It was 
expected that it would be difficult for some patients to respond to contact and answer a 
telephone call (particularly from an unknown caller). It is also possible that patients may 
initially have agreed to hear more about the study when approached by clinic staff but later 
felt less motivation to follow through and respond to a letter. It has already been noted that 
recruitment rates were higher when a researcher was present in the clinic when the patient 
agreed to hear more about the study and one reason for this may be that the patient had 
the opportunity to learn more about the study whilst they were still motivated and 
receptive to participation. Nevertheless, the target population – community patients with a 
diagnosis of treatment-resistant schizophrenia – are a hard-to-recruit population and 
recruitment difficulties were expected. Future studies that aim to recruit from this 
population should aim to provide further information about the study as soon as possible 
after an initial expression of interest from the patient.  
Owing to the opening of only two study sites rather than three, the recruitment 
target was reduced proportionally and the revised target was met. However, the smaller 
sample means that estimates of the key parameter in the primary outcome measure (the 
Drooling Rating Scale) is likely to be a more imprecise estimate than would have resulted 
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from a larger sample. A smaller sample size also means that the probability of detecting 
adverse events is reduced.  
Nevertheless, the trial was able to provide informative data that met the trial aims; 
recruitment and retention rates were successfully estimated, and metrics of the primary 
outcome measure were obtained to inform a future sample size calculation. The research 
team gathered valuable experience of recruiting participants from community clozapine 
clinics and appreciated the importance of effective communication with clinic staff and 
patients, as well as engaging patients and informal caregivers in the communication and 
promotion of research. 
Our conclusion is that a large, multicentre RCT using a placebo arm and telephone 
interviews is feasible in a trial assessing the effectiveness of medications for clozapine 
induced hypersalivation.  
 
List of abbreviations 
BACS: Brief Assessment of Cognition in Schizophrenia, CIH: clozapine-induced 
hypersalivation, CONSORT: Consolidated Standards of Reporting Trials, DRS: Drooling Rating 
Scale, GCP: Good Clinical Practice, IMP: investigational medicinal product, LUNSERS: 
Liverpool University Neuroleptic Side-Effect Rating Scale, MAHSC-CTU: Manchester 
Academic Health Sciences Centre-Clinical Trials Unit, NHRS: Nocturnal Hypersalivation 
Rating Scale, RCT: randomised controlled trial 
 
DECLARATIONS 
 
Ethics approval and consent to participate 
Ethical approval for the study was granted by the Health Research Authority, North West - 
Greater Manchester East Research Ethics Committee (reference 15/NW/0823). All 
participants provided full written informed consent to take part in the study.  
 
Consent for publication 
Consent to publish anonymized data and direct quotations from interviews in scientific and 
medical journals was obtained from participants. 
 
Availability of data and materials 
The datasets used and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
 
Competing interests 
The authors declare that they have no competing interests. 
 
15 
 
Funding 
This paper presents independent research funded by the National Institute for Health 
Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference 
Number PB-PG-0214-33069). The views expressed are those of the author(s) and not 
necessarily those of the NHS, the NIHR or the Department of Health and Social Care. 
 
Authors' contributions 
IQ is the Chief Investigator. IQ, SC, RD, IC, JFWD and NH designed the study. IQ, VH and SC 
wrote the trial protocol and designed the trial procedures. VH collected trial data and 
assisted with exit interviews. SC managed the trial and conducted the data analysis. IQ and 
SC drafted the manuscript. All authors read and approved the final manuscript. 
 
Acknowledgements 
The authors would like to acknowledge the invaluable and timely assistance of Farah Lunat, 
Anharul Islam, Nafeesa Bhatti, Aqeela Bhikha and Don Bryant during the data collection 
phase of the trial. 
  
16 
 
REFERENCES 
1. National Collaborating Centre for Mental Health (UK). Psychosis and Schizophrenia in 
Adults. Treatment and Management. Updated Edition. London: National Institute for 
Health and Care Excellence; 2014. 
2. Maher S, Cunningham A, O’Callaghan N, Byrne F, McDonald C, McInerney S, Hallahan B. 
Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on 
quality of life. Ther Adv Psychopharmacol. 2016;6:178–184. 
3. Safferman A, Lieberman JA, Kane JM. Update on the clinical efficacy and side-effects of 
clozapine. Schizophr Bull. 1991;17:247-261. 
4. Brodkin ES, Pelton GH, Price LH. Treatment of clozapine-induced parotid gland swelling.  
Am J Psychiatry 1996;153:445-445.  
5. Qurashi I, Stephenson P,  Chu S, Duffy C, Husain N, Chaudhry I. An evaluation of 
subjective experiences, effects and overall satisfaction with clozapine treatment in a UK 
forensic service. Ther Adv Psychopharmacol. 2015;5:146–150. 
6. British National Formulary (62). London: British Medical Association and the Royal 
Pharmaceutical Society. 
7. Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, Xia J. Pharmacological interventions for 
clozapine-induced hypersalivation. Cochrane DB Syst Rev. 2008;3:CD005579.  
8. Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: A review of 
treatment strategies. Can J Psychiatry 2007;52:377-384.  
9. Bird A, Smith T, Walton A. Current treatment strategies for clozapine-induced 
sialorrhea. Ann Pharmacother. 2011;45:667-669. 
10. Segev A, Evans A, Hodsoll J, Whiskey E, Sheriff RS, Shergill S, MacCabe JH. Hyoscine for 
clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled 
cross-over trial. Int Clin Psychopharmacol. 2019;34:101-107. 
11. Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and 
management strategies. Psychopharmacology 2006;185:265-273. 
12. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 12th ed. 
Chichester: Wiley Blackwell; 2015. 
13. Sherman SJ, Atri A, Hasselmo ME, Stern CE, Howard, MW. Scopolamine impairs human 
recognition memory: Data and modeling. Behav Neurosci. 2003;117:526-539. 
14. Green, MF. What are the functional consequences of neurocognitive deficits in 
schizophrenia? Am  J Psychiatry 1996;153:321–330. 
15. Mirakhur RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. Anaesthesia 
1983;38:1195–1204. 
16. Liang, C. S., Ho, P. S., Shen, L. J., Lee, W. K., Yang, F. W., Chiang, K. T. Comparison of the 
efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced 
sialorrhea in schizophrenic patients: A randomized, double-blind, crossover study. 
Schizophr Res. 2010;119:138-144.  
17 
 
17. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA, on 
behalf of the PAFS consensus group. CONSORT 2010 statement: extension to 
randomised pilot and feasibility trials. Pilot Feasibility Stud. 2016;2:64–732. 
18. Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the 
reduction of drooling. Dysphagia 1988;3:73-78. 
19. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 
2005;4: 287–291. 
20. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for Planning Pilot 
Studies in Clinical and Translational Research. CTS Clin Transl Sci 2011;4:332-337. 
21. Schoenfeld D. Statistical considerations for pilot studies. Int J Radiat Oncol. 1980;6:371-
74. 
22. Spivak B, Adlersberg S, Rosen L, Gonen N,  Mester R, Weizman A. Trihexyphenidyl 
treatment of clozapine-induced hypersalivation. Int Clin Psychopharm. 1997;12:213-5. 
23. Keefe RSE, Poe M, Walker TM, Harvey PD. The relationship of the Brief Assessment of 
Cognition in Schizophrenia (BACS) to functional capacity and real world functional 
outcome. J Clin Exp Neuropsyc. 2006;28:260-269. 
24. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief 
Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a 
standard neurocognitive battery.  Schizophr Res. 2004;68:283-297. 
25. Day JC, Wood G, Dewey, M, Bentall, RP. A self-rating scale for measuring neuroleptic 
side-effects: Validation in a group of schizophrenic patients. Brit J Psychiat. 
1995;166:650-53. 
 
18 
 
Figure 1: CONSORT diagram showing key stages of study design 
 
 
  
Consent & final eligibility checks 
Randomization 
Allocated to Glycopyrrolate arm Allocated to Placebo arm Allocated to Hyoscine arm 
Baseline visit (start of week 1) 
Complete BACS, NHRS, DRS, LUNSERS 
Week 1 Hyoscine (low dose) 
delivered to Participant; double blind 
 
Baseline visit (start of week 1) 
Complete BACS, NHRS, DRS, LUNSERS 
Week 1 Glycopyrrolate (low dose) 
delivered to Participant; double blind 
Baseline visit (start of week 1) 
Complete BACS, NHRS, DRS, LUNSERS 
Week 1 Placebo (low dose)  
delivered to Participant; double blind 
 
enrollment 
allocation 
intervention phase 
Medication collection visit & start of washout period (if participant taking prior hypersalivation medication) 
Maintenance visit (end of Week 1) 
Complete NHRS, DRS, LUNSERS; 
Week 2-4 Hyoscine (reg. dose) 
delivered to Participant; double blind 
 
Maintenance visit (end of Week 1) 
Complete NHRS, DRS, LUNSERS; 
Week 2-4 Glycopyrrolate (reg. dose) 
delivered to Participant; double blind 
 
Maintenance visit (end of Week 1) 
Complete NHRS, DRS, LUNSERS; 
Week 2-4 Placebo (reg. dose) 
delivered to Participant; double blind 
 
Telephone Call 1 (end of Week 2); complete NHRS, DRS, LUNSERS 
 
Telephone Call 2 (end of Week 3); complete NHRS, DRS, LUNSERS 
 
Final visit (end of Week 4); complete BACS, NHRS, DRS, LUNSERS 
End of trial; exit interview (optional) 
19 
 
Figure 2: CONSORT diagram showing the number of patients who consented to contact, 
were randomized, were followed-up and complete datasets analysed.  
 
 
 
 Rec’d consent to contact (n = 138) 
Randomised (n = 29) 
Excluded (n = 109) 
  - Not eligible (n = 8) 
  - Declined to participate (n = 26) 
  - No response to contact (n = 54) 
  - Other (n = 21) 
Allocated to Glycopyrrolate (n = 9) 
- Received Glycopyrrolate (n = 9) 
Allocated to Placebo (n = 11) 
- Received Placebo (n = 11) 
Allocated to Hyoscine (n = 9) 
- Received Hyoscine (n = 5) 
- Did not receive Hyoscine (n = 4) 
 Changed mind about  
                     participation (n = 2) 
 Suffered bereavement (n = 1) 
 No response to contact (n = 1) 
 
Lost to follow-up (n = 1) 
-  Data from P10 was not lodged by 
    the research assistant 
Lost to follow-up (n = 2) 
-  Data from P3 and P4 was not lodged  
    by the research assistant 
Lost to follow-up (n = 1) 
-  Data from P9 was not lodged by 
    the research assistant 
  
Discontinued intervention (n = 2) 
-   P18 and P25 withdrew from study 
    owing to concerns about side effects 
Assessed for objective 1  (n = 4) 
Assessed for objective 2 (n = 4) 
Assessed for objective 1 (n = 7) 
Assessed for objective 2 (n = 7) 
Assessed for objective 1 (n = 10) 
Assessed for objective 2 (n = 10) 
 
enrollment 
allocation 
follow-up 
assessment 
